Every material Form 8-K IDEX filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
IDEX reported record third-quarter 2026 net sales of $952 million, up 8% from a year earlier, and diluted EPS of $1.95, up 15%. The company raised its full-year 2026 guidance for organic sales growth and adjusted diluted EPS, which gives shareholders a higher outlook for the year.
Q3 net sales of $951.7 million rose 8%; organic sales also rose 8%, with orders up 13% to $991.2 million
Diluted EPS attributable to IDEX was $1.95 versus $1.70; adjusted diluted EPS was $2.33 versus $2.03, up 15%
Full-year adjusted diluted EPS guidance raised to $8.91 to $8.96 from $8.70 to $8.85
Full-year organic sales growth guidance raised to 6.5% to 6.8% from 5% to 6%
IDEX Corporation amended and restated its credit agreement on September 3, 2026, establishing an $800 million revolving credit facility that matures September 3, 2031, extended from November 1, 2027. The filing describes the facility as a senior unsecured arrangement that can fund working capital, general corporate purposes and refinancing of existing debt, which gives the company longer-dated borrowing capacity.
Revolving facility of $800 million with final maturity of September 3, 2031, up from November 1, 2027 under the original agreement
Up to $100 million available for letters of credit and up to $50 million for same-day swingline loans
Lender commitments may be increased by up to $400 million, and the maturity may be extended twice by one year each
IDEX Corporation disclosed that director L. Paris Watts-Stanfield resigned from its Board effective immediately on August 13, 2026. The company said the resignation was not due to any disagreement over its operations, policies or practices. The board size was reduced from ten to nine directors as a result.
Director L. Paris Watts-Stanfield resigned from the Board effective immediately, with the decision dated August 13, 2026.
The company stated the resignation was not due to any disagreement on operations, policies or practices.
Board size was reduced from ten to nine directors.
IDEX reported second-quarter 2026 net sales of $921 million, up 6% from a year earlier, and diluted EPS of $1.93, up 11%. The company raised its full-year 2026 organic sales growth guidance to 5% to 6% and its adjusted diluted EPS guidance to $8.70 to $8.85, both above prior ranges, which is a direct positive for shareholders.
Q2 2026 net sales of $921 million rose 6% reported and 5% organically; adjusted diluted EPS of $2.32 rose 12%.
Full-year 2026 adjusted diluted EPS guidance raised to $8.70 to $8.85 from $8.35 to $8.55.
Full-year organic sales growth guidance raised to 5% to 6% from 3% to 4%.
IDEX returned $77 million through share repurchases and $54 million in dividends in the quarter.
IDEX reported first quarter 2026 net sales of $886.9 million, up 9% on a reported basis and 5% organically, and reported diluted EPS of $1.61, up from $1.26. The company raised its full-year 2026 organic sales and adjusted diluted EPS guidance, which signals higher expected earnings for shareholders.
Q1 2026 net sales of $886.9 million rose 9% reported and 5% organically; reported diluted EPS was $1.61 versus $1.26 a year earlier.
Full-year 2026 organic sales growth guidance raised to 3% to 4%, up from 1% to 2%.
Full-year 2026 adjusted diluted EPS guidance raised to $8.35 to $8.55, up from $8.15 to $8.35.
Gross margin fell to 44.9% from 45.3%; the company repurchased $76 million of shares and paid $53 million in dividends in the quarter.
IDEX notified Roopa Unnikrishnan, a named executive officer serving as Senior Vice President and Chief Strategy and Innovation Officer, on February 4, 2026, that her position is being eliminated effective February 28, 2026. The company expects to enter a separation agreement with her under her letter agreement for a termination without cause, and the filing gives no financial terms. The change is an executive departure with no stated effect on financial results or guidance.
Position of Senior Vice President and Chief Strategy and Innovation Officer eliminated; notice given February 4, 2026
Effective date of separation is February 28, 2026
Separation expected to be a termination without cause under existing letter agreement, described in the March 26, 2025 proxy statement
Filing does not disclose separation payment amounts
IDEX reported fourth-quarter 2025 net sales of $899.1 million, up 4% on a reported basis and 1% organically, with reported diluted EPS of $1.71, up 6%. For full year 2025, sales rose 6% to $3.5 billion, but reported diluted EPS fell 3% to $6.41, while adjusted diluted EPS rose 1% to $7.95. The company also projected 2026 adjusted diluted EPS of $8.15 to $8.35.
Q4 2025 net sales $899.1 million, up 4% reported and 1% organic; Q4 reported diluted EPS $1.71, up 6%
Full year 2025 net sales $3,457.5 million, up 6%; reported diluted EPS $6.41, down 3%
Full year 2025 adjusted diluted EPS $7.95, up 1%; operating cash flow $680.4 million
2026 outlook: full year adjusted diluted EPS $8.15 to $8.35; full year organic sales up 1% to 2%
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every IDEX filing is on SEC EDGAR ↗. 8-K briefs of other companies →